HCA Healthcare Inc HCA

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

HCA Healthcare (HCA) is back in focus after five affiliated Texas hospitals filed suit against Independence Blue Cross, alleging more than $345,000 in unpaid claims between 2022 and 2024. At a share price of US$438.12, HCA Healthcare has seen a 2.85% 1 day share price return and a 12.99% 90 day share price return. Total shareholder return of 7.73% over one year and 80.41% over three years points to momentum that has built over time, even as the year to date share price return is down 6.86%,...

Despite a $2.8 billion settlement over BlueCard program disputes, five HCA-affiliated hospitals say the program still traps them in red tape.

ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell sai

HCA Healthcare, Inc. (NYSE:HCA) announced on September 15 that it had completed its acquisition of The College of Health Care Professions. The institution serves more than 8,000 students annually through 10 Texas campuses and online programs, offering more than 20 accredited healthcare programs. For HCA Healthcare, Inc. (NYSE:HCA), the opportunity is to connect education more […]

Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) President and CTO Nicolas Loebel spoke with Proactive's Stephen Gunnion about the company's photodisinfection technology, top-line results from its pivotal phase III LANTERN trial, and the commercial opportunity for Steriwave. The 5,188-patient phase III LANTERN study, conducted across 18 major US and Canadian hospitals, showed a 40.5% lower risk of 30-day surgical site infections. Loebel said the findings "change the entire nature of the company," highlighting a favourable safety profile with no device-related serious adverse events. He discussed the

NASHVILLE, Tenn., September 15, 2026--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that it has completed the previously announced acquisition of The College of Health Care Professions (CHCP).

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that Ed Jones has joined the firm as an Operating Partner.